COMBINED INHIBITION OF TOP1 AND PARP: A NOVEL THERAPEUTIC STRATEGY FOR GBM WITH PTEN DEFICIENCY

被引：0

作者：

Kim, Olga ^{[1
]}

Butler, Madison ^{[2
]}

Robey, Robert ^{[2
]}

Chari, Raj ^{[3
]}

Sergi, Zach ^{[4
]}

Zhang, Meili ^{[3
]}

Pang, Ying ^{[4
]}

Yu, Guangyang ^{[3
]}

Zhang, Wei ^{[3
]}

Song, Hua ^{[3
]}

Davis, Dionne ^{[3
]}

Wang, Herui ^{[4
]}

Merchant, Mythili ^{[4
]}

Ranjan, Alice ^{[4
]}

Gilbert, Mark ^{[1
]}

Gottesman, Michael ^{[3
]}

Pommier, Yves ^{[5
]}

Wu, Jing ^{[1
]}

机构：

[1] NCI, NIH, Neurooncol Branch, Bethesda, MD USA

[2] NCI, NIH, Bethesda, MD USA

[3] NIH, Bethesda, MD USA

[4] NCI, NOB, Bethesda, MD USA

[5] NCI, Bethesda, MD USA

来源：

NEURO-ONCOLOGY | 2022年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EXTH-63

引用

页码：223 / 223

页数：1

共 50 条

[1] COMBINED TOP1 AND PARP INHIBITION ENFORCES GENOMIC INSTABILITY AND CELL DEATH IN PTEN-DEFICIENT GLIOBLASTOMA
Kim, Olga
Butler, Madison
Pang, Ying
Yu, Guangyang
Merchant, Mythili
Ranjan, Alice
Gilbert, Mark
Pommier, Yves
Wu, Jing
NEURO-ONCOLOGY, 2021, 23 : 163 - 163
[2] PARP1 INHIBITION AS A NOVEL THERAPEUTIC TARGET FOR KELOID DISEASE
Park, Tae Hwan
Park, Yun Joo
WOUND REPAIR AND REGENERATION, 2019, 27 (03) : A40 - A40
[3] PARP1 Inhibition as a Novel Therapeutic Target for Keloid Disease
Park, Tae Hwan
Kim, Chan Woo
Choi, Jin Sik
Park, Yun Joo
Chong, Yosep
Park, Min Ji
Cho, Yuri
ADVANCES IN WOUND CARE, 2019, 8 (05) : 186 - 194
[4] PI3 KINASE AND CHECKPOINT INHIBITION: A POTENTIALLY NOVEL THERAPEUTIC STRATEGY FOR GLIOBLASTOMA (GBM)
Jalali, Ali
Siddik, Abu Bakar
Yu, Kwanhu
Tobin, Richard P.
Hay, Charles E.
Aminkeng, Folefac
Fonkem, Ekokobe
Newell-Rogers, M. Karen
NEURO-ONCOLOGY, 2024, 26
[5] CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo
Meng, Wei
Wang, Jiajia
Wang, Baocheng
Liu, Fang
Li, Meng
Zhao, Yang
Zhang, Chenran
Li, Qifeng
Chen, Juxiang
Zhang, Liye
Tang, Yujie
Ma, Jie
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 5747 - 5758
[6] PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
Bian, X.
Gao, J.
Luo, F.
Rui, C.
Zheng, T.
Wang, D.
Wang, Y.
Roberts, T. M.
Liu, P.
Zhao, J. J.
Cheng, H.
ONCOGENE, 2018, 37 (03) : 341 - 351
[7] PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
X Bian
J Gao
F Luo
C Rui
T Zheng
D Wang
Y Wang
T M Roberts
P Liu
J J Zhao
H Cheng
Oncogene, 2018, 37 : 341 - 351
[8] Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Bardia, Aditya
Sun, Sheng
Thimmiah, Nayana
Coates, James T.
Wu, Bogang
Abelman, Rachel O.
Spring, Laura
Moy, Beverly
Ryan, Phoebe
Melkonyan, Mark N.
Partridge, Ann
Juric, Dejan
Peppercorn, Jeffrey
Parsons, Heather
Wander, Seth A.
Attaya, Victoria
Lormil, Brenda
Shellock, Maria
Nagayama, Aiko
Bossuyt, Veerle
Isakoff, Steven J.
Tolaney, Sara M.
Ellisen, Leif W.
CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2917 - 2924
[9] Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma
Peng, Xin
Huang, Xin
Zhang, Shaolu
Zhang, Naixin
Huang, Shengfan
Wang, Yingying
Zhong, Zhenxing
Zhu, Shan
Gao, Haiwang
Yu, Zixiang
Yan, Xiaotong
Tao, Zhennan
Dai, Yuxiang
Zhang, Zhe
Chen, Xi
Wang, Feng
Claret, Francois X.
Elkabets, Moshe
Ji, Ning
Zhong, Yuxu
Kong, Dexin
ADVANCED SCIENCE, 2024, 11 (30)
[10] DEVELOPMENT OF A NOVEL PRECLINICAL GBM MODEL AND THERAPEUTIC IMPACT OF IRE1 INHIBITION
Le Reste, P.
Pineau, R.
Jouan, F.
Samal, J.
Jegou, G.
Patterson, J.
Vauleon, E.
Avril, T.
Pandit, A.
Chevet, E.
NEURO-ONCOLOGY, 2019, 21 : 57 - 58

← 1 2 3 4 5 →